Approval · Notice of Compliance 22936 · 2019
ADCETRIS: Notice of Compliance 22936
Issued November 22, 2019
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 22936
- Date
- November 22, 2019
- Company
- Seattle Genetics Inc
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Priority
- Reason
- New indication: the treatment of previously untereatd adult patients with systemic anaplastic large cell lymphoma (salcl), peripheral T-cell lymphoma not otherwiase specified (ptcl-nos) or angioimmunoolastic T-cell lymphoma (aitl) whose tumours express cd30 in combination with cyclophosphamide, doxorubicin and prednisone
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ADCETRIS | Not yet assigned | — |
Medicinal ingredients
- BRENTUXIMAB VEDOTIN 50 MG per VIAL